Type 1 Diabetes

Discover groundbreaking findings from the FINE-ONE trial on finerenone, offering hope for type 1 diabetes patients with CKD.

Finerenone significantly reduces UACR in type 1 diabetes patients with chronic kidney disease, offering new hope for treatment.

Stay up to date with the groundbreaking FDA decisions, critical trial updates, and more news from the last month.

Alterations in appetite and weight may have influenced abdominal adiposity, as well as inflammatory and cardiometabolic markers.

FDA launches the Commissioner’s National Priority Voucher program, expediting drug reviews for critical health needs.

A total of 8 acute and chronic disease factors, including hypertension, obesity, and physical inactivity, compound to increase mortality and CVD risk.

An audio recap of the top 5 stories in healthcare news from the week of 10/12-18.

The sBLA for insulin human Inhalation Powder in children and adolescents with type 1 or type 2 diabetes was assigned a PDUFA target action date of May 29, 2026.

A recent study indicates the potential benefits of consistent follow-up in diabetes through tele-education, teleconsultation, and digital data support.

Investigators urge clinicians to support teenage patients with type 1 diabetes in managing their blood sugar and transitioning to adult care.

The Q3 recap for endocrinology spotlights major FDA decisions, new guidelines for managing diabetes during pregnancy, and major clinical trial updates.

Lifelong reliance on insulin, constant glucose monitoring, and management of hypo- and hyperglycemia require substantial lifestyle changes.

Yale researchers reveal that 17 million U.S. adolescents and young adults qualify for GLP-1RA therapy, highlighting barriers to access and insurance coverage.

Pediatric patients with type 1 diabetes often have severely limited access to care, allowing very few to achieve HbA1c goals.

In addition to type 1 and 2 diabetes, diabetic retinopathy substantially increases the risk of developing and worsening uveitis.

A technology review from the University of Virginia analyzes the successes of AID devices, as well as indicating where the technology still has to go.

Lexicon aims to address concerns from a 2024 complete response letter, which cited an increased risk of diabetic ketoacidosis.

Perceived changes in glucose metabolism and regulation in turn lead to more severe reported menopausal symptoms.

Investigators have cited population growth and epidemiological improvements as leading causes for the significant jump in cases.

Discover key advancements in endocrinology from July 2025, including FDA approvals and trial results.

Isaacs, Bellini, and Levy discuss a currently recruiting trial investigating CGM metrics in pregnant individuals with type 1 diabetes.

Isaacs and Bellini cover 3 of the most pivotal trial results from the 85th annual American Diabetes Association conference in part 1 of this 2-part recap.

Hosts discuss the US launch of the Twiist from Sequel Med Tech and what it means for care providers and people with diabetes.

June 2025 highlights groundbreaking advancements in endocrinology, featuring key insights from major conferences on diabetes, heart health, and kidney care.

Hosts sit down for a deep dive into The Diabetes Collective and what it's like operating a diabetes clinic in the modern healthcare landscape.